

Press release

Regulated Information - Transparency Statement

Disclosure in accordance with Belgian Law of 2 May 2007 – Transparency Law

Leuven, Belgium, 10 May 2019 – Pursuant to article 15 of the Belgian Law of 2 May 2007 regarding the publication of major holdings. Oxurion NV (Euronext Brussel: OXUR) publishes the following information:

Status as of 8 November 2018

- Total capital: € 147.976.946,87
- Total number of securities conferring voting rights: 38,291,950 shares
- Total number of voting rights (denominator): 38,291,950 (one vote per share)

Reason of change

Capital increase on 8 November 2018, creation of new 20.375 shares following the exercising of warrants

For an overview of the history of capital, please consult the Oxurion company website at <https://www.oxurion.com/investors/shareholder-info/history-capital>

END

For further information please contact:

<u>Oxurion NV</u> Wouter Piepers, Global Head of Investor Relations & Corp Coms +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com	
EU - Citigate Dewe Rogerson David Dible/ Sylvie Berrebi Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com	US - LifeSci Public Relations Alison Chen +1 646-876-4932 achen@lifescipublicrelations.com

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company focused on transforming treatments to preserve vision in patients with diseases affecting the back of the eye. The company is currently developing a competitive pipeline of disease-modifying drug candidates for diabetic eye disease, a leading cause of blindness of people of working age worldwide.

Oxurion's most advanced drug candidate is THR-317, a PIGF inhibitor for the treatment of diabetic macular edema (DME), which is currently in a Phase 2 study in combination with Lucentis®. THR-317 is also being evaluated in a Phase 2 study for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1), a rare retinal disease that affects the macula and can lead to vision loss.

Oxurion has two further pipeline candidates, THR-149, a plasma kallikrein inhibitor being developed for the treatment of DME; and THR-687, a pan-RGD integrin antagonist in development for the treatment of diabetic retinopathy and DME. Both THR-149 and THR-687 are in Phase 1 clinical studies.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.